TagsNeurology 
Sildenafil Reduces Risk of Alzheimer’s Disease by Half

The first meta-analysis on the association between use of sildenafil, a Phosphodiesterase-5 (PDE5) inhibitor, and risk of Alzheimer’s disease (AD) was conducted by Singaporean researchers. MEDLINE and Embase were searched from inception to Mar...

Oct 24, 2025
Beyond LDL-C Reduction – A Discussion on the Neuroprotective Effect of Statin-based Therapy

Statins are the front-line therapeutic agents for preventing cardiovascular diseases (CVD) and atherosclerotic disorders related to hypercholesterolemia by lowering low-density lipoprotein cholesterol (LDL-C) levels 1 . In addition to this primary i...

Oct 24, 2025
Have Sweet Things Been On Your Mind? The Potential Neurocognitive Consequences of Sweeteners

Sweeteners arrived to the market as the silver-bullet alternative to the rising health risks of sugar. Companies proactively innovated and reformulated their products to offer a diet-friendly option for the health-conscious, and low and no-calorie s...

Oct 24, 2025
Could mushrooms be the answer to Parkinson’s disease?

Psilocybin, a natural psychedelic found in mushrooms, is known to improve depression and anxiety. In a recent pilot trial in patients with mild to moderate Parkinson’s disease, the compound has further led to improvements of motor and non-moto...

Jun 13, 2025
Get Moving to Combat Cognitive Decline

While the benefits of exercise are already recognized, a landmark randomized controlled trial has demonstrated that exercise could preserve cognitive function in sedentary elderly adults with mild cognitive impairment. Both moderate-high intensity a...

Jun 13, 2025
The Tingling for Relaxation – A Review on Autonomous Sensory Meridian Response (ASMR) and Its Clinical Impacts

The Autonomous Sensory Meridian Response (ASMR) is a pleasant tingling sensation, typically beginning on the scalp and spreading down the neck and spine, and is elicited by a range of specific auditory, visual, or tactile stimuli, such as whispering...

Jun 13, 2025
Cognitive Landscapes – Environmental Pathways to Dementia

Dementia affects millions of individuals globally, and prevention remains paramount. A recent systematic review which evaluated the relationship between environmental factors and cognitive decline revealed air pollutants, including particulate matte...

Apr 11, 2025
Improving Quality of Life in Parkinson’s Disease: Safinamide’s Impact beyond Motor Symptoms

Case Presentation A 72-year-old man, previously diagnosed with Parkinson’s disease (PD) 10 years ago, presented with persistent end-of-dose resting tremor despite regular follow-up at a public hospital. He was partially dependent in his activi...

Apr 11, 2025
Improving Somnolence with Once-daily Perampanel Tablet in Epileptic Patients: A Case Report

Case Presentation A 35-year-old male, diagnosed with generalised tonic-clonic seizures (GTCS) in May 2023 following his hospitalization in China for his first seizure attack, consulted Dr. Fung’s clinic due to complaints of somnolence that has...

Feb 17, 2025
AQUIPTA®

AQUIPTA® (Atogepant) ABBVIE HK Reg. No. HK-68287 (03 Jul, 2024) & HK-68288 (03 Jul, 2024) Composition: 1 Aquipta® (Atogepant) is an orally administered, small molecule, selective calcitonin gene-related peptide (CGRP) receptor antagonist...

Oct 22, 2024
LEQEMBI®

LEQEMBI® (lecanemab) EISAI HK Reg. No. HK-68289 (03 Jul, 2024) & HK-68290 (03 Jul, 2024) Composition: 3 LEQEMBI® is an amyloid beta-directed antibody with the active ingredient lecanemab-irmb. It is administered as an intravenous infusio...

Aug 20, 2024